呼吸指南

订阅

MedSci主页 / 所有栏目 / 呼吸指南

国际中医临床实践指南：慢性阻塞性肺疾病

2020-04-20 世界中医药学会联合会 世界中医药.2020.15(7):1084-1092.

慢性阻塞性肺疾病

慢性阻塞性肺疾病（ＣＯＰＤ）是严重危害公众健康的重大慢性疾病。中医药防治ＣＯＰＤ具有较好的临床疗效，并获得了一些显著成果。为进一步完善诊疗规范，促进中医诊治水平的提高，更好地指导慢阻肺中医临床诊疗工作

中文标题：

国际中医临床实践指南：慢性阻塞性肺疾病

发布机构：

世界中医药学会联合会

发布日期：

2020-04-20

简要介绍：

慢性阻塞性肺疾病（ＣＯＰＤ）是严重危害公众健康的重大慢性疾病。中医药防治ＣＯＰＤ具有较好的临床疗效，并获得了一些显著成果。为进一步完善诊疗规范，促进中医诊治水平的提高，更好地指导慢阻肺中医临床诊疗工作，世界中医药学会联合会组织专家小组，在中华中医药学会２０１９年发布的《慢性阻塞性肺疾病中医诊疗指南》（标准号：Ｔ／ＣＡＣＭ１３１９-２０１９）基础上，评估最新海内外临床研究证据，修订转化形成《国际中医临床实践指南　慢性阻塞性肺疾病》并进行双语发布。指南内容主要包括前言、引言、范围、规范性引用文件、术语和定义、疾病诊断分期、严重程度评估、病因病机、辨证论治、其他治法、预防调护、附录１２个部分，规范了慢阻肺的中医病因病机、辨证论治、预防调护的内容。该指南适用于于中医、中西医结合临床呼吸内科医师。该指南发布将有助于提升中医药防治慢阻肺水平。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=国际中医临床实践指南：慢性阻塞性肺疾病.pdf)] GetToolGuiderByIdResponse(projectId=1, id=5a72a1c00190011b, title=国际中医临床实践指南：慢性阻塞性肺疾病, enTitle=, guiderFrom=世界中医药.2020.15(7):1084-1092., authorId=0, author=, summary=慢性阻塞性肺疾病（ＣＯＰＤ）是严重危害公众健康的重大慢性疾病。中医药防治ＣＯＰＤ具有较好的临床疗效，并获得了一些显著成果。为进一步完善诊疗规范，促进中医诊治水平的提高，更好地指导慢阻肺中医临床诊疗工作, cover=https://img.medsci.cn/202055/1588681170991_2020535.jpg, journalId=0, articlesId=null, associationId=1898, associationName=世界中医药学会联合会, associationIntro=世界中医药学会联合会, copyright=0, guiderPublishedTime=Mon Apr 20 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>慢性阻塞性肺疾病（ＣＯＰＤ）是严重危害公众健康的重大慢性疾病。中医药防治ＣＯＰＤ具有较好的临床疗效，并获得了一些显著成果。为进一步完善诊疗规范，促进中医诊治水平的提高，更好地指导慢阻肺中医临床诊疗工作，世界中医药学会联合会组织专家小组，在中华中医药学会２０１９年发布的《慢性阻塞性肺疾病中医诊疗指南》（标准号：Ｔ／ＣＡＣＭ１３１９-２０１９）基础上，评估最新海内外临床研究证据，修订转化形成《国际中医临床实践指南　慢性阻塞性肺疾病》并进行双语发布。指南内容主要包括前言、引言、范围、规范性引用文件、术语和定义、疾病诊断分期、严重程度评估、病因病机、辨证论治、其他治法、预防调护、附录１２个部分，规范了慢阻肺的中医病因病机、辨证论治、预防调护的内容。该指南适用于于中医、中西医结合临床呼吸内科医师。该指南发布将有助于提升中医药防治慢阻肺水平。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=2115, tagName=慢性阻塞性肺疾病)], categoryList=[CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=37, categoryName=中医科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2115, guiderKeyword=慢性阻塞性肺疾病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3572, appHits=311, showAppHits=80, pcHits=874, showPcHits=3311, likes=3, shares=25, comments=13, approvalStatus=1, publishedTime=Tue May 05 20:43:48 CST 2020, publishedTimeString=2020-04-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Tue May 05 20:19:34 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 17:34:50 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=国际中医临床实践指南：慢性阻塞性肺疾病.pdf)])
国际中医临床实践指南：慢性阻塞性肺疾病.pdf
下载请点击：
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1191183, encodeId=c2f4119118337, content=这个写得非常好，有实用价值，值得推广, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:29:04 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064198, encodeId=86ca10641989a, content=hao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98fc5648249, createdName=ms3000001796531437, createdTime=Tue Oct 26 21:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959164, encodeId=4299959164df, content=感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/80b5ecba92d34c2189008744cb41a1c0/790aaa8dde6e438bad8124a88d513ae1.jpg, createdBy=91d55431472, createdName=ms2000001371769580, createdTime=Wed Apr 21 20:36:25 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953973, encodeId=6bdf9539e34b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe5443590, createdName=ms5000002009642071, createdTime=Mon Apr 05 17:03:43 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902370, encodeId=115e9023e029, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21741851196, createdName=ms1266624407159746, createdTime=Thu Nov 26 08:22:33 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
    2022-02-08 ms3000000637975859

    这个写得非常好，有实用价值，值得推广

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1191183, encodeId=c2f4119118337, content=这个写得非常好，有实用价值，值得推广, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:29:04 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064198, encodeId=86ca10641989a, content=hao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98fc5648249, createdName=ms3000001796531437, createdTime=Tue Oct 26 21:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959164, encodeId=4299959164df, content=感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/80b5ecba92d34c2189008744cb41a1c0/790aaa8dde6e438bad8124a88d513ae1.jpg, createdBy=91d55431472, createdName=ms2000001371769580, createdTime=Wed Apr 21 20:36:25 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953973, encodeId=6bdf9539e34b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe5443590, createdName=ms5000002009642071, createdTime=Mon Apr 05 17:03:43 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902370, encodeId=115e9023e029, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21741851196, createdName=ms1266624407159746, createdTime=Thu Nov 26 08:22:33 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
    2021-10-26 ms3000001796531437

    hao

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1191183, encodeId=c2f4119118337, content=这个写得非常好，有实用价值，值得推广, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:29:04 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064198, encodeId=86ca10641989a, content=hao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98fc5648249, createdName=ms3000001796531437, createdTime=Tue Oct 26 21:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959164, encodeId=4299959164df, content=感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/80b5ecba92d34c2189008744cb41a1c0/790aaa8dde6e438bad8124a88d513ae1.jpg, createdBy=91d55431472, createdName=ms2000001371769580, createdTime=Wed Apr 21 20:36:25 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953973, encodeId=6bdf9539e34b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe5443590, createdName=ms5000002009642071, createdTime=Mon Apr 05 17:03:43 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902370, encodeId=115e9023e029, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21741851196, createdName=ms1266624407159746, createdTime=Thu Nov 26 08:22:33 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
    2021-04-21 ms2000001371769580

    感谢！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1191183, encodeId=c2f4119118337, content=这个写得非常好，有实用价值，值得推广, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:29:04 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064198, encodeId=86ca10641989a, content=hao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98fc5648249, createdName=ms3000001796531437, createdTime=Tue Oct 26 21:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959164, encodeId=4299959164df, content=感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/80b5ecba92d34c2189008744cb41a1c0/790aaa8dde6e438bad8124a88d513ae1.jpg, createdBy=91d55431472, createdName=ms2000001371769580, createdTime=Wed Apr 21 20:36:25 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953973, encodeId=6bdf9539e34b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe5443590, createdName=ms5000002009642071, createdTime=Mon Apr 05 17:03:43 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902370, encodeId=115e9023e029, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21741851196, createdName=ms1266624407159746, createdTime=Thu Nov 26 08:22:33 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
    2021-04-05 ms5000002009642071

    好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1191183, encodeId=c2f4119118337, content=这个写得非常好，有实用价值，值得推广, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:29:04 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064198, encodeId=86ca10641989a, content=hao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98fc5648249, createdName=ms3000001796531437, createdTime=Tue Oct 26 21:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959164, encodeId=4299959164df, content=感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/80b5ecba92d34c2189008744cb41a1c0/790aaa8dde6e438bad8124a88d513ae1.jpg, createdBy=91d55431472, createdName=ms2000001371769580, createdTime=Wed Apr 21 20:36:25 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953973, encodeId=6bdf9539e34b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe5443590, createdName=ms5000002009642071, createdTime=Mon Apr 05 17:03:43 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902370, encodeId=115e9023e029, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21741851196, createdName=ms1266624407159746, createdTime=Thu Nov 26 08:22:33 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
    2020-11-26 ms1266624407159746

    好

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

慢性阻塞性肺疾病基层诊疗指南（2018年）

中华医学会呼吸病学分会慢性阻塞性肺疾病学组 · 2018-12-13

2018 NICE指南：慢性阻塞性肺疾病（急性加重）的处方抗菌药应用（NG.114）

暂未更新 · 2018-12-05

2018 KATRD临床实践指南：慢性阻塞性肺疾病（修订版）

韩国结核和呼吸疾病学会(KATRD,Korean Academy of Tuberculosis and Respiratory Diseases) · 2018-06-19

慢性阻塞性肺疾病药物临床试验规范

国家呼吸系统疾病临床医学研究中心 · 2018-01-23

慢性阻塞性肺疾病患者非肺部手术麻醉及围手术期管理专家共识

中华医学会麻醉学分会 · 2017-10-31

慢性阻塞性肺疾病急性加重的治疗策略：2017欧洲呼吸学会/美国胸科学会指南解读

暂未更新 · 2017-09-20

拓展阅读

2013年慢性阻塞性肺疾病诊治指南（修订版）

中华医学会呼吸病学分会慢性阻塞性肺疾病学组 · 2013-04-01

2014 ACCP/CTS指南：预防慢性阻塞性肺疾病急性发作

美国胸科医师学会(ACCP,American College of Chest Physicians) · 2014-10-16

ICSI：2016慢性阻塞性肺疾病（COPD）的诊断和处理

临床系统改进协会(ICSI,Institute for Clinical Systems Improvement) · 2016-05-12

2013 慢性阻塞性肺疾病诊治指南（2013年修订版）

中华医学会呼吸病学分会慢性阻塞性肺疾病学组 · 2014-01-03

慢性阻塞性肺疾病诊断、处理和预防全球策略 (2017GOLD报告)解读

暂未更新 · 2017-01-11

2017 年GOLD慢性阻塞性肺疾病诊断、治疗及预防的全球策略解读

暂未更新 · 2017-01-30